8-K: Synaptogenix Creates New Series C Convertible Preferred Stock, Secures $5 Million in Private Placement

Synaptogenix, Inc. has filed a Certificate of Designations creating a new Series C Convertible Preferred Stock and completed a $5 million private placement.

Summary

• Synaptogenix, Inc. has created a new series of preferred stock called Series C Convertible Preferred Stock.
• These preferred shares are convertible into common stock at an initial price of $4.00 per share, subject to adjustments.
• The company will redeem the preferred shares in equal quarterly installments starting October 31, 2024, with payments at 107% of the installment amount.
• Holders of the preferred shares are entitled to a 5% annual dividend, compounded quarterly, payable in cash, which increases to 15% upon a triggering event.
• The company completed a private placement of these preferred shares and warrants, raising $5 million before fees and expenses.
• The preferred shares have voting rights equivalent to common stock, with the number of votes based on the stated value divided by $3.52.
• Holders can require the company to redeem their shares in cash after the first anniversary of issuance.
• The company is seeking stockholder approval to issue more than 19.99% of its outstanding common stock, with a meeting planned no later than December 31, 2024.

Sentiment

Score: 7

Explanation: The document is generally positive as it details a successful capital raise, but there are some risks and complexities associated with the terms of the preferred stock. The sentiment is moderately positive as the company has secured funding, but the terms of the deal are complex and could have negative implications.

Positives

• The company has secured $5 million in funding through a private placement.
• The preferred shares offer a 5% annual dividend, providing a return for investors.
• The conversion feature allows investors to potentially benefit from increases in the company's common stock price.
• The redemption feature provides a mechanism for investors to exit their position after one year.
• The voting rights of the preferred shares give investors a say in company matters.

Negatives

• The conversion price is subject to adjustments, which could dilute the value of the common stock.
• The company is required to redeem the preferred shares, which could strain its cash flow.
• The dividend rate increases to 15% upon a triggering event, which could be costly for the company.
• The company's ability to settle conversions is limited until stockholder approval is obtained.
• The preferred shares have certain beneficial ownership limitations.

Risks

• The conversion price is subject to adjustments, which could dilute the value of the common stock.
• The company is required to redeem the preferred shares, which could strain its cash flow.
• The dividend rate increases to 15% upon a triggering event, which could be costly for the company.
• The company's ability to settle conversions is limited until stockholder approval is obtained.
• The preferred shares have certain beneficial ownership limitations.
• Failure to meet certain obligations, such as filing a registration statement or making payments, can trigger a redemption event.
• The company is subject to various covenants that restrict its ability to incur debt, make investments, and transfer assets.

Future Outlook

The company will seek stockholder approval to issue more than 19.99% of its outstanding common stock, which is necessary for full conversion of the preferred shares. The company will also be making quarterly redemption payments starting October 31, 2024.

Management Comments

• Robert Weinstein, Chief Financial Officer of Synaptogenix, signed the Certificate of Designations.

Industry Context

This announcement is typical of a biotech company seeking funding to advance its research and development. The use of convertible preferred stock is a common method for raising capital in this sector, offering investors a combination of income and potential equity upside. The terms of the preferred stock, including the conversion price, dividend rate, and redemption features, are designed to attract investors while providing the company with the necessary capital.

Comparison to Industry Standards

• The use of convertible preferred stock is a common financing method for biotech companies, similar to companies like Amylyx Pharmaceuticals and Cassava Sciences, which have also used this method to raise capital.
• The 5% dividend rate is within the typical range for preferred stock in the biotech sector, although some companies may offer higher or lower rates depending on their financial situation and risk profile.
• The initial conversion price of $4.00 per share is a key factor for investors, and its attractiveness will depend on the company's future performance and the market's perception of its value.
• The redemption feature after one year is a common provision in these types of financings, providing investors with a potential exit strategy.
• The various triggering events and covenants are standard protections for investors in these types of transactions, similar to those seen in other biotech financings.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the conversion of preferred shares.
• Employees may be affected by the company's financial stability and ability to execute its business plan.
• Creditors will be impacted by the company's new debt obligations and covenants.
• Customers and suppliers may be affected by the company's ability to continue operations and fulfill its obligations.

Next Steps

• The company will seek stockholder approval to issue more than 19.99% of its outstanding common stock.
• The company will begin making quarterly redemption payments on October 31, 2024.
• The company will need to manage its cash flow to meet the redemption obligations and dividend payments.

Key Dates

Keywords

preferred stock, convertible securities, private placement, capital raise, redemption, dividends, conversion price, voting rights, stockholder approval, Synaptogenix